Hollands Simone, Lim Yen Ying, Buckley Rachel, Pietrzak Robert H, Snyder Peter J, Ames David, Ellis Kathryn A, Harrington Karra, Lautenschlager Nicola, Martins Ralph N, Masters Colin L, Villemagne Victor L, Rowe Christopher C, Maruff Paul
School of Psychology, Royal Melbourne Institute of Technology, Bundoora, VIC, Australia.
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia Department of Neurology, Warren Alpert School of Medicine of Brown University & Lifespan Hospital System, Providence, RI, USA.
J Alzheimers Dis. 2015;43(2):677-86. doi: 10.3233/JAD-140678.
The detection of early Alzheimer's disease (AD) can rely on subjective and informant reports of cognitive impairment. However, relationships between subjective cognitive impairment, objectively measured cognitive function, and amyloid-β (Aβ) biomarkers remain unclear.
To determine the extent to which impairment or decline in subjective and informant rated cognitive impairment was associated with memory in healthy older adults with high Aβ.
Healthy older adults (n = 289) enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study were studied at baseline. Pittsburgh Compound B was used to determine Aβ status at baseline. At baseline and 18 months assessments, subjective memory impairment was assessed using the Memory Complaint Questionnaire and the Short Form of the Informant Questionnaire on Cognitive Decline in the Elderly. Cognition was measured using the Cogstate Brief Battery.
At baseline, there were no differences between low and high Aβ groups in subjective or informant-rated cognitive impairment, depressive and anxiety symptoms, or cognitive function. Longitudinal analyses showed moderate decline in learning and working memory over the 18 months in the high Aβ group. However there was no change over time in subjective or informant-rated cognitive impairment, depressive and anxiety symptoms, or cognition in either Aβ group.
Although healthy older adults with high Aβ levels show decline in learning and working memory over 18 months, subjective or informant ratings of cognitive impairment do not change over the same period suggesting subjective cognitive impairment may have limited utility for the very early identification of AD.
早期阿尔茨海默病（AD）的检测可依赖于认知障碍的主观报告和知情者报告。然而，主观认知障碍、客观测量的认知功能与淀粉样蛋白-β（Aβ）生物标志物之间的关系仍不明确。
确定在Aβ水平较高的健康老年人中，主观和知情者评定的认知障碍的损害或下降与记忆相关的程度。
对参与澳大利亚成像、生物标志物和生活方式（AIBL）研究的289名健康老年人进行基线研究。使用匹兹堡化合物B在基线时确定Aβ状态。在基线和18个月评估时，使用记忆投诉问卷和老年人认知衰退知情者问卷简表评估主观记忆障碍。使用Cogstate简短电池组测量认知功能。
在基线时，低Aβ组和高Aβ组在主观或知情者评定的认知障碍、抑郁和焦虑症状或认知功能方面没有差异。纵向分析显示，高Aβ组在18个月内学习和工作记忆有中度下降。然而，两组Aβ组的主观或知情者评定的认知障碍、抑郁和焦虑症状或认知功能随时间均无变化。
尽管Aβ水平较高的健康老年人在18个月内学习和工作记忆出现下降，但同期主观或知情者对认知障碍的评定没有变化，这表明主观认知障碍在AD的极早期识别中可能效用有限。
Zotero 插件